The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
about
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaPhase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersPET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasPredictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive LymphomaNext-generation prognostic assessment for diffuse large B-cell lymphomaConsolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspectiveTreatment of diffuse large B cell lymphomaRole of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceInterim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin LymphomaNext-generation surveillance strategies for patients with lymphomaPrognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabThe Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchDiffuse large B-cell lymphoma: current strategies and future directionsLong-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphomaHuman T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab eraCorrelations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma.Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review.B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.
P2860
Q24599100-1BC49738-24CB-45D7-86A2-B0052AB967EFQ24646379-84289DF7-E6C8-47A3-BC30-607F385BCCEBQ26752284-C58447A2-D8B9-4A61-89A9-BC92BABB86D8Q26771059-3BF57B25-566C-4108-A4BE-A682D6F56C42Q26796428-69921D55-E482-4251-8E25-BCD035C6D8B5Q26998446-7C32254B-8F79-4D67-AEDF-17A8384B29ECQ27006062-4A96641C-85C3-4C01-AACD-E6F9E54B5D7DQ27016561-0BC48FE5-D7E1-460D-9AEB-67C64F4D7FD8Q27023579-86AED7D6-7F7A-4E78-B96D-B4B641C78513Q27314782-EC9574E3-7B0A-4CA3-A5A4-5EED7B688658Q27314809-91AF9C95-F990-4B28-9133-2445A7E0E607Q28071905-91A80C91-55B2-4CAD-B9A4-66E0C6A3FCA8Q28084956-D82FF702-C719-4AE5-8B4B-7D2BC7CB2EF8Q28256567-CC51C5F8-FACC-4213-87C4-319B5FE9BD63Q28266484-15D4FBB9-DA7F-4ABF-9647-B027367379A7Q28269136-AFCBF7BB-8137-4D8E-BD69-A1F2DEE33FB5Q28297940-58C34D84-42F7-4FDB-ACD6-364019273DADQ30275206-CBC9C33E-17A0-4CCA-BDBF-97EE049AC2F4Q30653421-5ACDEA00-9CDF-48F9-956F-A2A65F819A43Q30967984-D48E7377-E441-4291-8960-08E95714C73EQ31116522-9E09DE63-3860-4A5F-B04D-A91913DC321EQ33396833-69F13FDE-648A-4072-995E-3E4ED9273970Q33397845-91F56A44-40F3-41F1-B170-AD899B431DAFQ33406444-9BD920A5-9C9E-4588-9E95-622DE126A3DBQ33407197-B8319ED6-085B-4DBB-A14A-8FEC3E567213Q33558130-7BDF4D21-1049-43D0-9C47-89A5EE1EFAF0Q33587666-5BF96A22-B187-44ED-88CD-D97B28E50505Q33608527-E9D6AA3A-E471-48E1-B20E-1771B0242F7AQ33622342-91A2D389-5F9A-4FF3-A067-E14D35FFC4B0Q33625864-62992D86-34F1-41D6-BE71-3EFC2C95E90EQ33701858-272A807A-AFA6-4B5C-A5A1-FDCFE0AC2208Q33701863-68BE7F87-E935-42C0-80DE-14745E43CBA6Q33710715-875EB8E0-7449-451E-8F94-5F8D937162E3Q33710720-475F6780-C339-40DE-86BF-4F48DD816D3AQ33718809-566B249E-8B07-41CC-A00F-A8773310F6E5Q33739574-D4B711F3-CAC1-4486-9082-0F51DDD890E6Q33809728-C65BDED4-1BBE-4CF4-B802-257307F9AC5BQ33846399-2B754425-66B7-42F8-AB6D-3D0166B11BD1Q33846801-3D0985CE-D8FD-4DCA-A671-242E57A3808CQ33875883-0EF75A87-92A3-4E54-9C43-DCE97B1E807C
P2860
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The revised International Prog ...... l lymphoma treated with R-CHOP
@ast
The revised International Prog ...... l lymphoma treated with R-CHOP
@en
The revised International Prog ...... l lymphoma treated with R-CHOP
@nl
type
label
The revised International Prog ...... l lymphoma treated with R-CHOP
@ast
The revised International Prog ...... l lymphoma treated with R-CHOP
@en
The revised International Prog ...... l lymphoma treated with R-CHOP
@nl
prefLabel
The revised International Prog ...... l lymphoma treated with R-CHOP
@ast
The revised International Prog ...... l lymphoma treated with R-CHOP
@en
The revised International Prog ...... l lymphoma treated with R-CHOP
@nl
P2093
P3181
P1433
P1476
The revised International Prog ...... l lymphoma treated with R-CHOP
@en
P2093
Brian Berry
Catherine Fitzgerald
Judy Sutherland
Karamjit Gill
Kerry J Savage
Laurie H Sehn
Mukesh Chhanabhai
Paul Hoskins
Richard Klasa
Tamara Shenkier
P304
P3181
P356
10.1182/BLOOD-2006-08-038257
P407
P577
2007-03-01T00:00:00Z